Pharmacology and DMPK

Novalink: A better translation

Move closer to market with our therapeutic area expertise, in vitro assays, in vivo models and deep understanding of both disease and drug mode of action. Our custom solutions help connect preclinical efficacy with clinical success.

Cultivating a candidate

Novalix has assembled all the disciplines, expertise and techniques that make a world-class pharmacology partner.

Biochemical assays

As part of our first-class in vitro biology services, we offer: a broad range of enzymatic assays; (kinases, epigenetic enzymes, nucleotide exchange factors; nuclear receptors); and binding biochemical assays (BRET, HTRF, AlphaLISA). Our experts can design customized assays that will help you select the best compounds on your projects.

Cellular and primary tissue assays

A customizable, comprehensive range of target-based and phenotypic cellular assays to identify and optimize compounds/biologics, understand their mechanism of action and validate the target engagement. The cellular models can be cell lines, primary cells (patient derived cells) or tissue (explants).

ADME-PK and preformulation

A rigorous suite of assays to test compound profile: in vitro ADME assays, in vivo PharmacoKinetics, as well as batch analysis and formulation design. 

in vivo pharmacology

An extensive panel of relevant models and readouts to assess novel drug potential in key therapeutic areas: immuno-inflammation, oncology, fibrosis, kidney diseases, metabolic disorders, infectious diseases and osteoarthritis.

Histology

Decipher spatial context related to disease pathology and target expression, through IHC (immunohistochemistry), ISH (in situ hybridization), and special stains highlighting specific proteins, mRNA, or structure modification at the tissue level.

Biobank

Find the most relevant translational model to assess your drug efficacy and mechanism of action. Access healthy and/or diseased fresh, frozen or fixed biosamples using our ready-to-use inventory of proprietary samples or biosourcing of prospective collection (Human biospecimens and associated clinical data).

PK/PD

A vital stage between lead optimization and candidate selection, the combination of pharmacokinetics and pharmacodynamics give a clearer understanding of effective drug dose, absorption, excretion and interaction.

Biomarkers

Biomarkers are critical to establishing the activity, efficacy, and safety of a drug in development. Our technologically advanced instrumentation and data computation afford greater precision in biomarker discovery and drug evaluation before clinical trials.

Therapeutic areas

Oncology
Immuno-inflammation
Virology
Antibacterials
Infectious diseases
Fibrosis
Kidney diseases
Osteoarthritis
Metabolic disorders

Meet our experts

Some of the key leaders on the Novalix team in our Pharmacology and DMPK platform

Viviane Brel

VP Pharmacology

More than 20 years of experience in drug discovery in big pharma (Sanofi/Pierre Fabre) from target proposal to clinical trials. Cell biology, oncology, immuno-oncology.

Stephanie Lavazais

Associate director in vitro Biology/Biomarkers/Biobank

Translational sciences, immunology, biomarkers. Expert in immunology with in-depth understanding of drug mode of action. Experience in setting up whole blood assays to deliver clinical biomarkers.

Anne Gigout

Associate director in vitro Biology/Biomarkers/Biobank

More than 15 years of experience in drug discovery (Merck, Galapagos). in vivo models, osteoarthritis. Responsible for immunology in vivo platform. Expert in osteoarthritis field.

Lionel Trottet

Director DMPK Pharmacokinetics and ADME

More than 25 years of experience in drug discovery. DMPK representative in drug discovery projects in big pharma and biotech (GSK, Galapagos).

Novalink at work